Five things for pharma marketers to know: Thursday, November 10, 2016

1. Mylan reported a third-quarter loss, due in part to a charge for a settlement over allegations about Medicaid pricing of the EpiPen. Revenue came in below expectations for the company as volume of the allergy autoinjector dropped. (WSJ)

2. Analysts say that the Trump presidency will lessen the likelihood of restrictions on drug pricing. However, one analyst noted that there is an “overall shift toward greater pricing scrutiny that will continue to reduce potential revenue growth purely from price increases.” (NYT)

3. The FDA issued a rule that limits the use of citizen petitions to delay approval of generic drugs or biosimilars. Critics have said that the petitions are used less to raise scientific or safety concerns than to delay competition. (Stat)

4. Pfizer is urging the courts to dismiss a lawsuit brought by two former sales reps who allege that the drugmaker gave kickbacks to physicians to drive off-label use of the antipsychotic Geodon. Pfizer reportedly used speaker programs to distribute the kickbacks. (Law360)

5. Bristol-Myers Squibb will pay Nitto Denko, a Japanese drugmaker, $100 million to acquire an experimental treatment for liver fibrosis due to fatty liver disease NASH or hepatitis C. The deal also gives BMS the exclusive option to license Nitto's experimental drugs for lung fibrosis and other organ fibrosis in the future. (Reuters)